The overall adverse event ( AE ) incidence was 73.3 % , 77.9 % , and 78.4 % with canagliflozin 100 and 300 mg and glimepiride ; the incidence of AE-related discontinuations was low across groups ( 6.2 % , 9.5 % , and 7.3 % , respectively ) .